-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target

Benzinga·04/09/2025 12:41:16
Listen to the news
Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $60 price target.